Prevalence of Hyperkalemia in Type 2 Diabetics Treated with Inhibitors of the Renin-Angiotensin-Aldosterone System: A Multicenter Study
Journal of Surgery
Volume 4, Issue 2-1, March 2016, Pages: 4-9
Received: Oct. 13, 2015; Accepted: Oct. 14, 2015; Published: Nov. 30, 2015
Views 3901      Downloads 98
Abeer Al Saweer, Consultant Family Physician, Arabian Gulf University, Manama, Bahrain
Reda Othman, Consultant Family Physician, Ministery of Health, Manama, Bahrain
Article Tools
Follow on us
Background and Aim: Hyperkalemia is a common risk among patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors, especially diabetics. The aim of this study was to measure the prevalence of hyperkalemia among patients with type-2 diabetics treated with ARBs and/or ACEIs, and compare them with controls. Subjects and methods: This study was carried out in four primary health care centers in Bahrain using a comparative ex-post-facto cross-sectional design with a control group. It included 305 type-2 diabetes patients in these settings. They were categorized into four groups: A) controls not on RAAS medications; B) ARB alone; C) ACE Inhibitors alone; D) combination of both. Data were collected from medical records. The study protocol was approved by the research committee in the Ministry of Health in the Kingdom of Bahrain. Results: The prevalence of hyperkalemia among those on ACE inhibitor and/or ARB medications was 16.51% (95% CI: 11.84 – 22.12%), while severe hyperkalemia was 1.38% (95% CI: 0.28 – 3.97%). The patients in the group taking both ARB and ACE inhibitor medications had significantly higher level of serum potassium but better control of their Fasting Blood Sugar (FBS) compared to the other 3 groups. In multivariate analysis, the medication group was not a statistically significant predictor of hyperkalemia. Conclusion: A combined ACEi/ARB therapy may pose a higher risk of increased serum potassium compared with mono-treatment or control. Hence, caution should be exercised especially in those with advanced kidney disease, heart failure, on renal replacement therapy, on potassium sparing diuretics.
Diabetes, Hyperkalemia, Renin-Angiotensin-Aldosterone, Potassium
To cite this article
Abeer Al Saweer, Reda Othman, Prevalence of Hyperkalemia in Type 2 Diabetics Treated with Inhibitors of the Renin-Angiotensin-Aldosterone System: A Multicenter Study, Journal of Surgery. Special Issue: Gastrointestinal Surgery: Recent Trends. Vol. 4, No. 2-1, 2016, pp. 4-9. doi: 10.11648/j.js.s.2016040201.12
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bakris G.L., Pitt B., Weir M.R., Freeman M.W., Mayo M.R., Garza D., Stasiv Y., Zawadzki R., Berman L., Bushinsky D.A., AMETHYST-DN Investigators. (2015): 14Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA.; 314(2):151-61. doi: 10.1001/jama.2015.7446.
Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., and Zelmanovitz T. (2005): Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care; 28:176-188.
Winkelmayer W.C., Fischer M.A., Schneeweiss S., Wang P.S., Levin R., and Avorn J. (2005): Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis; 46:1080–1087.
Chan J.C., Ko G.T., and Leung D.H. (2000): Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int; 57: 590-600.
Parving H.H., Hovind P., Rossing K., and Andersen S. (2001): Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens; 10: 515–522.
Magnus N.C., and Jackson E. (2000): Intractable life-threatening hyperkalemia in a diabetic patient. Nephrol Dial Transplant; 15(1): 113-4.
Jarman P.R., and Mather H.M. (2003): Diabetes may be independent risk factor for hyperkalemia. BMJ; 327(7418): 812
Palmer B.F. (2004): Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med;351:585–592.
Mount D.B., and Zandi-Nejad K. (2007): Disorders of potassium balance. In: Brenner BM, Levine SA, editors. Brenner and Rector’s The Kidney, 8th ed. Philadelphia: Saunders Elsevier;547–587.
LeeJ.H., KwonY.E., ParkJ.T., LeeM.J., OhH.J., HanS.H., Kang S.W., ChoiK.H., and YooT.H. (2014): The effect of renin–angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia. Journal of Renin-Angiotensin-Aldosterone System; 15 (4): 491-497.
Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS.A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009 ;5(3):547-52.
Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Clin Ther. 2011 ;33(4):456-64.
Cheng J, Zhang X, Tian J, Li Q, Chen J. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract. 2012 ;66(10):917-23.
Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol. 2010 :8(6):742
Park I, Sheen SS, Lim HS, Yoon D, Park MY, Lee SH, Shin GT, Kim H, Park RW. Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database. Am J Cardiovasc Drugs. 2012 1;12(4):255
Raebel M.A., Ross C., and Cheetham C. (2010): Increasingly restrictive definitions of hyperkalemia outcomes in a database study: Effect on incidence estimates. Pharmacoepidemiol Drug Saf;19:19–25.
Ministry of health. Bahrain (2012): Publications/statistics/HS2012/PDF/Chapters/CH08-Primaryhealthcare_2012.pdf. Accessed on 13/7/2013
American Diabetes Acssociation, USA. accessed on 5.7.2013.
American Association of Clinical Chemistry, (2013): USA. Accessed on 5.7.2013.
Weir M.R., and RolfeM. (2010): Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. CJASN; 5(3): 531-548.
de Denus S., Tardif J.C., White M., Bourassa M.G., Racine N., and Levesque S. (2006): Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J; 152:705–712.
Desai A.S., Swedberg K., and McMurray J.J.V. (2007): Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM program. J Am Coll Cardiol;50:1959–1966.
Bakris G.L., Oparil S., Purkayastha D., Yadao A.M., Alessi T., and Sowers J.R. (2013): Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich).; 15(2):92-100. doi: 10.1111/jch.12032. Epub 2012 Oct 26.
Susantitaphong P., Sewaralthahab K., and Balk E.M. (2013): Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens; 26:424.
Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsärinne K., Oto A., Parkhomenko A., Piegas L.S., Svendsen T.L., Teo K.K., Yusuf S., ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet; 372: 547–553.
Mann J., Anderson C., and Gao P. (2013): Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens.;31(2):414-421.
Juarez G.F., Luno J., and Barrio V. (2012): Effects of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial. Am J Kidney Dis.; 1-8.
Fried L.F., Emanuele N., Zhang J.H., Brophy M., Conner T.A., Duckworth W., Leehey D.J., McCullough P.A., O’Connor T., Palevsky P.M., Reilly R.F., Seliger S.L., Warren S.R., Watnick S., Peduzzi P., Guarino P., VA NEPHRON-D Investigators, (2013): Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med; 369: 1892–1903.
Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides M., Richard A., Xiang Z., Brunel P., Pfeffer M.A., ALTITUDE Investigators (2012): Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med; 367: 2204–2213.
Mallat S.G. (2013): Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? Cardiovascular Diabetology; 12:108.
Appel G.B., Radhakrishnan J., Avram M.M., DeFronzo R.A., Escobar-Jimenez F., Campos M.M., Burgess E., Hille D.A., Dickson T.Z., Shahinfar S., Brenner B.M. RENAAL Study. (2003): Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care.; 26(5):1402-7.
Priston R, David Afshartous, Dyal Garg, Sergio Medrano, Alberto B.Alonso, Ronaldo Rodriguez (2009): Mechanisms of impaired potassium handling with dual renin- angiotensin- aldosterone blockad in chronic kidney disease. Hpertenion 53: 754-760.
Bakris G.L., Weir M.R., Shanifar S., Zhang Z., Douglas J., van Dijk D.J., Brenner B.M., RENAAL Study Group. (2003): Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 14; 163(13):1555-65.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186